Considering other studies, up-regulating Mcl-1 in melanoma cells is proposed to boost tumor cells resistance to TRAIL-mediated apoptosis, while combination therapy with Mcl‐1‐selective inhibitor S63845 with TRAIL improved robust apoptosis in TRAIL-resistant melanoma cells, and thereby confirmed the influential role of the Mcl-1 in determining the cell responses to TRAIL (21). This evidence concerns the gene TNFSF10 and melanoma.